3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Neoplasms
5
Healthy Participants
5
Breast Neoplasms
5
Prostatic Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Venous Thromboembolism
2
Solid Tumor, Adult
2
Neoplasm Metastasis
2
Healthy Volunteers
2
Endometrial Neoplasms
2
Colorectal Neoplasms
2
Cardiovascular Diseases
2
cMET-dysregulated Advanced Solid Tumors
1
Venous Thrombosis
1
TP53 Y220C Mutation
1
Stroke
1
Sarcoma, Synovial
1
Sarcoma, Alveolar Soft Part
1
Sarcoma
1
Rectal Neoplasms
1
Pulmonary Embolism
1
Prostatic Neoplasms, Castration-Resistant
1
Precancerous Conditions
1
Peripheral Nervous System Diseases
1
Pain
1
Ovarian Neoplasms
1
Multiple Endocrine Neoplasia Type 1
1
Melanoma
1
Liver Cirrhosis
1
Leiomyosarcoma
1
Interventions
Doxorubicin
6
Ifosfamide
5
Radiotherapy
4
pazopanib
3
cediranib
3
atezolizumab
3
Sunitinib
3
selinexor
2
perifosine
2
pembrolizumab
2
Trabectedin
2
Specimen Handling
2
Loperamide
2
Gemcitabine
2
Filgrastim
2
Dacarbazine
2
Cisplatin
2
Biopsy
2
Bevacizumab
2
trifluridine tipiracil drug combination
1
spartalizumab
1
sargramostim
1
romidepsin
1
lentiviral minigene vaccine of COVID-19 coronavirus
1
ixazomib
1
indolepropanol phosphate
1
futibatinib
1
fludarabine
1
cabozantinib
1
brostallicin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Sarcoma, Alveolar Soft Part
×
Rosuvastatin Calcium
×
Clear all
NCT03016819
2026-02-25
APROMISS
Advenchen Laboratories, LLC
Phase 3
Recruiting
325 enrolled